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Abstract
Background: Vitamin D has several reported immunomodulatory properties including the reduced generation of
pro-inflammatory CD4+ T helper 1 (Th1) cells and the increase in levels of the anti-inflammatory Th2 subset. Less
clear has been the impact of vitamin D on the pro-inflammatory Th17 subset, and whether and how vitamin D
may preferentially drive the polarization of one of the T helper subsets.
Methods: Using human peripheral blood-derived mononuclear cells and mouse splenocytes and lymph node cells
in culture, we examined whether and how vitamin D preferentially skews T cells towards the Th1, Th2 or Th17
subsets. Mice afflicted with the multiple sclerosis-like condition, experimental autoimmune encephalomyelitis (EAE),
were examined in vivo for the relevance of the tissue culture-derived results.
Results: We report that the biologically active form of vitamin D, 1,25-dihydroxyvitamin D3 {1,25(OH)2D3},
consistently generates human and murine Th2 cells in culture, frequently leaving unchanged the levels of Th1/
Th17 cytokines. As a result, the ratio of Th2 to Th1 and Th17 is increased by 1,25(OH)2D3. The upregulation of Th2
to Th1 or Th17 subsets by 1,25(OH)2D3 is enabled by an increase of the GATA-3 transcription factor, which itself is
promoted upstream by an elevation of the STAT6 transcription factor. In mice, the alleviation of EAE severity by
1,25(OH)2D3 is accompanied by elevation of levels of GATA-3 and STAT6. Significantly, the efficacy of 1,25(OH)2D3
in ameliorating EAE is completely lost in mice genetically deficient for STAT6, which was accompanied by the
inability of 1,25(OH)2D3 to raise GATA-3 in STAT6 null lymphocytes.
Conclusions: These results of vitamin D promoting a Th2 shift through upstream GATA-3 and STAT6 transcription
factors shed mechanistic understanding on the utility of vitamin D in MS.
Background
Multiple sclerosis (MS) is an inflammatory and neurode-
generative disorder with widespread demyelination and
axonal loss within the central nervous system (CNS). The
underlying etiology remains undefined although both envir-
onmental and genetic factors play a role [1,2], resulting in
the over-activation of various immune subsets that accu-
mulate in the CNS to produce injury. Familial inheritance,
cigarette smoking, viral infection, and ultraviolet (UV) light
exposure may all contribute to the risk of MS [1,3].
Vitamin D deficiency has previously [4] and recently
been suggested as another contributing factor in the
pathogenesis of MS [5-7]. Several studies have reported
an inverse association of sunlight exposure, available UV
radiation and MS prevalence [5,8,9], implicating vitamin
D since UV B radiation (280 to 315 nm) converts 7-
dehydrocholesterol to previtamin D3 in the epidermal
and dermal layers in humans; previtamin D3 is then
converted by a thermal process to vitamin D3 [10]. Due
to the changing angle of declination of the sun, vitamin
D insufficiency is common in the winter months in lati-
tudes north of 42 °N latitude [11]. Therefore, vitamin D
is of interest as the biological correlate of available UV
radiation, although it has been proposed that other fac-
tors could also be involved [12].
In humans, vitamin D3 undergoes hydroxylation in the
liver to produce 25-hydroxyvitamin D3 {25(OH)D3}, the
main circulating form of vitamin D. 25(OH)D3 can be
further hydroxylated in the liver to 24,25-dihydroxyvita-
min D3, or in the kidney to the immunologically active
form of vitamin D, 1,25 dihydroxyvitamin D3 {1,25(OH)
2D3} [10,13]. Many publications {reviewed in [13-15]}
have reported extensively on the immunomodulatory
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decreases T cell proliferation, increases the activity and
frequency of regulatory T cells, alters the production
of specific antibody isotypes, reduces activity of dendritic
cells or makes them tolerogenic, and affects tissue-
specific lymphocyte homing.
Naïve CD4-positive T helper (Th) cells can differentiate
into either pro-inflammatory Th1 and Th17 subsets, or
into Th2 subset with anti-inflammatory or regulatory
activity [16,17]. Vitamin D has been found to elevate Th2
cytokines [18,19] and to reduce Th1 cytokine levels
[20,21]; however, others have also found vitamin D to inhi-
bit Th1 levels without affecting Th2 deviation [22], or to
reduce EAE disease severity without altering Th1 or Th2
levels [23]. These results emphasize that there needs to be
clarity on the activity and mechanism of vitamin D in CD4
Th1/Th2 differentiation. The literature on vitamin D and
Th17 cells is still emerging, and vitamin D has been
reported to reduce the level of Th17 cytokines in human
studies [24], and to decrease Th17 cells in mice with colitis
[25] or EAE [26].
Given the uncertain nature of the impact of vitamin D
on T cell subsets, and the recent analysis in genetically
altered or chimeric mice of the requirement of T cell
expression of vitamin D receptors for amelioration of
EAE [27], we have addressed the relationship between
vitamin D and Th subsets, focusing on whether 1,25(OH)
2D3 acts predominantly through altering one of the Th
subsets, and of the attendant mechanisms. We first ana-
lysed human and mouse T cells in culture, and then
extended to EAE studies. We elucidated a central role for
STAT6 in regulating the vitamin D-polarization of Th2
cells to alleviate disease activity.
Methods
Isolation of T Cells
Human peripheral blood mononuclear cells (PBMCs) were
isolated from the blood of healthy adult volunteers by
Ficoll-Hypaque centrifugation [28]. The PBMCs were
washed once with phosphate-buffered saline (PBS) and
suspended in serum-free AIM-V medium (Invitrogen Life
Technologies, Burlington, Ontario). To activate T cells in
the PBMC populations, 96 well round-bottomed plates
were coated with 10 or 1000 ng/mL of purified mouse
anti-human CD3 (BD Pharmingen, Franklin Lakes, NJ) for
a period of 3 h. From previous experiments (data not
shown), the coating at 1000 ng/mL of anti-CD3 gives max-
imal activation of T cells measured by proliferation assays.
Since the in vivo environment in humans is unlikely to
lead to the maximal activation of T cells, a submaximal
level of activation with 10 ng/ml anti-CD3 was also used
in most experiments as both a comparison to maximal
activation and to better reflect physiology. This submaxi-
mal level of activation may also permit the more sensitive
measurement of experimental changes that affect T cell
activation.
Human PBMCs were plated at a density of one million
cells/mL of anti-CD3 coated 96 well plates (200 μ L/well,
200,000 cells per well). An additional 10 ng/mL of anti-
CD28 (BD Pharmingen) was added as a suspension to all
cultures, and cells were left for 3 days at 37°C in a 5%
humidified CO2 incubator. In order to promote measur-
able levels of IL-17, some anti-CD3/CD28 activated cul-
tures were further exposed to IL-23 (20 ng/mL) and IL-1b
(10 ng/mL) [29] Specified sister cultures were further
exposed to either 0.1, 1 or 10 nM of 1,25(OH)2D3 (Bio-
Mol, Plymouth Meeting, PA). In some experiments, cer-
tain PBMC preparations did not receive anti-CD3 or 1,25
(OH)2D3, and the floating cells collected 3 days thereafter
are referred to as unactivated T cells.
Flow cytometry analyses of the floating cells collected
after 3 days of the initiation of anti-CD3 treatment indi-
cated that CD3+ T cells constituted approximately 90%
of the total cell population (data not shown). Of the CD3
c e l l s ,6 0 %w e r eC D 4 +a n d4 0 %w e r eC D 8 + .F o rt h e
remaining, approximately 8% were CD56+ natural killer
cells, approximately 2% were CD19+ B lymphocytes, and
less than 1% were CD14+ monocytes. There was no sig-
nificant difference in the proportion of the various cell
subsets between the unactivated, 10 and 1000 ng/mL
anti-CD3 activated PBMC populations (data not shown).
Since the majority of cells were T cells, henceforth this
human culture population is referred to as T cells.
Quantitative Real-Time polymerase chain reaction (qPCR)
For qPCR, T cell RNA was extracted using the RNeasy
Mini Kit columns (Qiagen, Mississauga, ON). DNase treat-
ment (M610A) was performed according to the manufac-
turer’s instructions (Promega, Madison, WI). Total RNA
extracted was reverse transcribed using Superscript II (Invi-
trogen). Resulting cDNA was subjected to real-time quanti-
tative PCR using an iCycler (BioRad). Transcripts were
quantified by real-time quantitative PCR on the iCycler
using RT2 Real Time SYBR Green/Fluorescein PCR Master
Mix (SA Biosciences, Frederick, MA). mRNA expression
for each gene was calculated using a comparative cycle
threshold method, and was normalized to the amount of
the reference gene 18S rRNA (expressed as arbitrary units).
All PCR primers were purchased from SA Biosciences (18S,
PPH05666E; IFNg, PPH00380B; IL-5, PPH00692A; IL-17,
PPH00537B; TBX21/T-bet, PPH00396A/PPM03727A;
GATA-3, PPH02143A/PPM05199A; RORC/RORgT,
PPH05877A/PPM25095A; STAT6, PPH00760B; Notch 1,
PPM04747A).
ELISA
Cytokine production by human and mouse PBMCs was
assessed after activation of cells for 72 h. Cytokines in
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to the manufacturer’s protocol. ELISA kits were pur-
chased from Invitrogen. The IL-17 was of the IL-17F
form. Data were analysed using a SpectraMax 384
(Molecular Devices Corporation, Sunnyvale, CA) accord-
ing to the manufacturer’s instructions.
Disease induction in mice and EAE analysis
EAE was induced in female C57BL/6 mice (Jackson
Laboratories, Bar Harbor, Maine), aged 8-9 weeks, by
injecting subcutaneously (s.c.) 50 μg myelin oligodendro-
cyte glycoprotein (MOG)35-55 in Complete Freund’sA d j u -
vant (CFA) (Fisher, Michigan USA) supplemented with 4
mg/ml of Mycobacterium tuberculosis on day 0 [30,31].
Intraperitoneal (i.p.) pertussis toxin (0.1 μg/200 μl, List Bio-
logical labs, Hornby, ON) was administered on days 0 and
2. 1,25(OH)2D3 (100 ng) was given every other day i.p. in
50 μLo fD M S O ,w h i l e5 0μL of DMSO was used as the
vehicle control; this method of administering 1,25(OH)2D3
to mice has been reported by others [18,19,26,32,33].
Treatment was initiated at the time of MOG immuniza-
tion. In addition to the wildtype mice, STAT6 -/- knockout
(KO) mice on the C57BL/6 background (Jackson Labora-
tories, Bar Harbour, Maine) were utilized. Animals were
assessed daily using a 15-point disease score scale [30,31]
replacing the more commonly used 5-point scale since the
15-point scale differentiates individual limb disability,
rather than grouping both fore- or hind-limbs together.
This allows for a more sensitive characterization of disease
progression. The 15-point scale is the sum of the disease
state for the tail (scored from 0-2) and all 4 limbs (each
limb is scored from 0-3). All animals were handled in
accordance with the policies outlined by the Canadian
Council for Animal Care and the University of Calgary.
Statistical Analysis
Statistical analysis was performed using R version 2.8.1
(The R Foundation for Statistical Computing) and Matlab
version 7.7 (The Mathworks, Natick, MA, USA). Statisti-
cal differences for cells in culture were addressed using
ANOVA with Bonferroni correction for multiple com-
parisons. Statistical differences between groups of mice
in the EAE experiments were evaluated using a nonpara-
metric analysis Mann-Whitney U test. An alpha of 0.05
was selected for statistical significance.
Results
1,25(OH)2D3 differentially shifts human T cells in favor of
Th2
We measured the changes in cytokine profile of T cells
cultured with 1,25(OH)2D3. Supernatants from human T
cells stimulated for 3 days with either 10 or 1000 ng/mL
of anti-CD3, to reflect low and maximal activation of T
cells, were analysed by ELISA for protein content of
representative cytokines: interferon-g (IFNg)f o rT h 1 ,
interleukin (IL)-5 for Th2, and IL-17 for Th17 cells.
Figure 1A shows that 1,25(OH)2D3 decreases IFNg and
IL-17 for both levels of anti-CD3 stimulation while
increasing IL-5, indicating an elevation of Th2 to Th1/17
cells.
To examine the individual human response to 1,25
(OH)2D3 more thoroughly, we next used qPCR of T cell
samples cultured from several individuals for 3 days at 10
and 1000 ng/mL (1000ng/mL shown) of anti-CD3 as
above. Figure 1B shows that the levels of IFNg and IL-17
mRNA tended to be inconsistent and to change variably
with 1,25(OH)2D3 treatment from one subject to the
n e x t ;t h u s ,l e v e l so fI F N g and IL-17 mRNA may be
increased, decreased, or unaltered for increasing concen-
trations of 1,25(OH)2D3. In contrast, IL-5 production
consistently increased with 1,25(OH)2D3 exposure rela-
tive to no treatment, leading to a consistent elevation of
the ratio of IL-5 to either IFNg or IL-17 across T cell
samples from the multiple subjects tested (Figure 1B).
The mRNA results thus verified the polarization of CD4+
T cell subsets that was suggested by the ELISA assays of
cytokines, with 1,25(OH)2D3 treatment consistently
favoring Th2 anti-inflammatory over pro-inflammatory
Th1 and Th17 subsets.
Specific transcription factors drive the formation of the
Th subsets and the mRNA generated above for cytokine
analyses were subjected to the levels of TBX21 for Th1,
GATA-3 for Th2, and RORC for Th17 subsets. Similar to
the above cytokine mRNA results, 1,25(OH)2D3 treatment
reproducibly elevated the level of GATA-3 transcription
factor mRNA across subjects, while producing variable
responses for TBX21 and RORC mRNA levels amongst
subjects (Figure 1C). When expressed as a ratio for both
levels of anti-CD3 activation, 1,25(OH)2D3 produced an
elevation of GATA-3 compared to TBX21 and RORC
across all subjects analysed. Thus, the overall effect of 1,25
(OH)2D3 on Th polarization could be attributed to its
predominance of driving the Th2 subset.
Murine cells respond similarly to human cells
We tested the response of murine T cells to 1,25(OH)
2D3 in culture in order to allow subsequent transition
to animal models. Mononuclear cells were isolated from
mouse spleens and lymph nodes and were cultured for
3 days while being unactivated or stimulated with either
10, 100 or 1000 ng/mL of anti-CD3. We found that
mouse IL-17 protein was difficult to detect reliably by
ELISAs. As with the human ELISA results, murine T
cells produce increasing concentrations of IL-5, but had
reduced concentrations of IFNg (Figure 2A), in response
to 1,25(OH)2D3. The ratio of IL-5 to IFNg protein
was thus increased with 1,25(OH)2D3 treatment
(Figure 2A).
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mulated with 1000 ng/mL anti-CD3. IL-5 and GATA-3
transcripts were consistently elevated with increasing
1,25(OH)2D3 concentrations while IFNg and IL-17
tended to be decreased. The ratios of IL-5 to IFNg and
IL-17 were thus upregulated with increasing concentra-
tions of 1,25(OH)2D3, as were the ratios of GATA-3 to
T-bet (the mouse equivalent of TBX21) and RORgT
(the mouse equivalent of RORC) (Figure 2B), confirming
a similar response in mouse and human cells.
STAT6 but not Notch1 is elevated in human PBMCs with
increasing 1,25(OH)2D3 concentrations
Since both IL-5 and GATA-3 were consistently elevated
with increasing 1,25(OH)2D3 concentrations, we
explored upstream factors that affect GATA-3 levels in
human cells. Several factors have been reported to
increase GATA-3 expression [34,35], including Notch1
and STAT6.
Human PBMCs stimulated with 10 ng/ml anti-CD3
were treated with 1nM of 1,25(OH)2D3 or left as
untreated controls. After 3 days, RNA was harvested and
analyzed using RT-qPCR. Figure 3A shows that the ratio
of STAT6 to TBX21 transcripts increased with 1,25(OH)
2D3 treatment, similar to the ratio of GATA-3 to
TBX21, while the ratio of Notch1 to TBX21 remained
constant. These results indicate that 1,25(OH)2D3 likely
acts through STAT6 to increase GATA-3 levels, with no
significant contribution through Notch1. Similar results
are noted for cells activated with both 10 and 1000ng/mL
of anti-CD3, and in the culture of murine PBMCs (data
not shown).
Figure 1 Cytokine and transcription factor analyses show that 1,25(OH)2D3 polarizes human T cells in favor of Th2 rather than the
Th1 and Th17 subsets. A) ELISA results for T cells activated with two concentrations of anti-CD3 (10 and 1000 ng/mL) demonstrate that IFNg
and IL-17 concentrations decrease (p < 0.001), while IL-5 concentrations increase (p < 0.05), with the addition of 0.1 nM 1,25(OH)2D3 (denoted
as Vit D in figure). Each bar is the mean ± SD of quadruplicate cultures and data displayed is from a single subject. The cytokine ratios were
significantly increased between treated and untreated groups (p < 0.001). When analyzed across T cells from 4 subjects, we found that one
subject did not alter IFNg or IL-17 levels with 1,25(OH)2D3 treatment but IL-5 was elevated. Thus, across subjects, the increased ratio of IL-5/IFNg
and IL-5/IL-17 is a consistent outcome for 1,25(OH)2D3 treatment. B) qPCR results for 1000 ng/mL anti-CD3 activated T cells from five human
donors (each line represents one donor) demonstrating that mRNA levels for both IFNg and IL-17 were variably affected by 1,25(OH)2D3, but
always increased for IL-5. In all five subjects, the ratio of IL-5 to both IFNg and IL-17 was elevated by increasing concentrations of 1,25(OH)2D3.
These results were reproduced in cells activated by 10 ng/mL anti-CD3 (data not shown). C) qPCR results of transcription factors for T cells from
five donors activated with 1000ng/mL anti-CD3 show that while levels of TBX21 (which regulates Th1 polarization) and RORC (Th17) were largely
unaltered by 1,25(OH)2D3, GATA-3 (which regulates Th2) transcripts were elevated, resulting in a consistent increase in the ratio of GATA-3 to
both TBX21 and RORC levels. These results were reproduced in cells activated by 10 ng/mL anti-CD3 (data not shown).
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We induced C57BL/6 wildtype mice for EAE and exam-
ined the amounts of GATA-3 and its potential regula-
tors, STAT6 and Notch1, in the spleen and lymph
nodes (Figure 3B) at peak clinical disease. To normalize
across samples and for ease of comparisons, we
expressed the results as a ratio to T-bet. We compared
these data between EAE mice treated with 1,25(OH)2D3
or vehicle.
EAE has previously been shown to be largely abrogated
with the treatment of 1,25(OH)2D3 [18,19,32,33,36,37].
We have reproduced this finding, and report here that
the treatment every other day with 1,25(OH)2D3 essen-
tially prevented C57BL/6 wildtype mice from succumbing
to EAE signs (Figure 4A). At termination of the clinical
scoring, spleens and lymph nodes were removed and
RNA was isolated for qPCR. Figure 3B shows that relative
to the vehicle treated EAE mice, the level of transcripts
encoding GATA-3 to T-bet was high in 1,25(OH)2D3-
treated wildtype mice. As well, levels of STAT6 but not
NOTCH1 were elevated by 1,25(OH)2D3 treatment.
STAT6 is required for the therapeutic effects of 1,25(OH)
2D3 on EAE
Given that the upregulation of Th2-associated cytokine
and transcription factor is paralleled by an increase of
STAT6, we addressed whether STAT6 influences the
therapeutic effect of 1,25(OH)2D3 in EAE. STAT6
knockout (KO) mice and wildtype controls were induced
for EAE, and both succumbed to EAE. While there was
a clear separation between the 1,25(OH)2D3-treated ani-
mals compared with the control animals in the wildtype
groups (Figure 4A), the therapeutic effect of 1,25(OH)
2D3 was lost when mice were without STAT6 (Figure
4B). These results emphasize that STAT6 is necessary
for 1,25(OH)2D3 to alleviate EAE.
Mice were killed at the conclusion of the EAE clinical
scoring above, and their spleens and lymph nodes were
Figure 2 Cytokines and transcription factors in mouse cells after 1,25(OH)2D3 treatment. A) ELISA results for T cells activated with
increasing concentrations of mouse anti-CD3 demonstrate increasing IFNg and IL-5 concentrations, but 1,25(OH)2D3 suppresses the IFNg
concentration while increasing the IL-5 concentration. This results in an increase in the IL-5 to IFNg ratio across all concentrations of anti-CD3.
Each bar is the mean ± SD of quadruplicate cultures and data displayed is from a single mouse, repeated 3 times. B) qPCR results for 100ng/mL
anti-CD3 demonstrate decreased IFNg and IL-17 mRNA and increased IL-5 mRNA for increasing concentrations of 1,25(OH)2D3. C) The ratio of IL-
5/IFNg and IL-5/IL-17 mRNA rises with increasing concentrations of 1,25(OH)2D3. Similarly, the ratio of mRNA for GATA-3/T-bet and GATA-3/ROR-
gT as determined by qPCR elevates with increasing concentrations of 1,25(OH)2D3.
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further manipulation of tissue. While wildtype mice
treated with 1,25(OH)2D3 clearly upregulated GATA-3
transcripts relative to T-bet, STAT6 KO mice did not
have this response (Figure 5A), further substantiating
the requirement of STAT6 for inducing an elevation of
GATA-3 transcripts.
At sacrifice of the mice in Figure 4, lymphocytes were
isolated and cultured for 3 days. Figure 5B shows that in
wildtype cells from EAE mice previously treated in vivo
with vehicle, the ex vivo treatment with 1,25(OH)2D3,
with or without MOG restimulation, increased the
GATA-3 to T-bet ratio. Significantly, the increase of
GATA-3 to T-bet that occurred in wildtype mice did not
occur in cells from the STAT6 KO mice (Figure 5C).
Overall, these results demonstrate that 1,25(OH)2D3
loses its therapeutic efficacy in EAE when STAT6 is
absent, and this corresponds with the inability of
STAT6 null cells to elevate GATA3 levels in response
to 1,25(OH)2D3.
Discussion
Evidence supporting the involvement of vitamin D in the
risk of MS include an inverse correlation between MS
prevalence and latitude that has been consistently
observed [8,9,38], strongly suggesting a latitudinally-
related environmental contribution to etiology. Available
ultraviolet radiation, inversely correlated to latitude, is
responsible for the peripheral conversion of 7-dehydro-
cholesterol to vitamin D3 in the epidermis. Therefore,
vitamin D may be the biological correlate of available
ultraviolet radiation conferring disease risk to a popula-
tion. In MS patients, there is evidence of a seasonality of
birth in MS patients (again suggestive of a seasonal envir-
onmental factor) [39], oral vitamin D intake appears to be
protective [7] and vitamin D levels correlate inversely
with disability [40]. In adult [41] or pediatric [42] MS
populations, incremental increases in serum 25-hydroxy-
vitamin D3 levels are associated with reduced propensity
for relapses. Two small trials have suggested that relapse
rates may be reduced in patients taking oral vitamin D
supplementation [43,44]. More recently, high dose intake
(average of 10,000 IU/day) of vitamin D over 1 year in a
study of 40 patients, appeared to reduce relapse rate in
MS [45].
There is an increasing appreciation that Vitamin D
exerts broad regulatory effects on cells of the adaptive
and innate immune system. These include reducing anti-
gen presentation through reducing the activity of dendri-
tic cells or promoting their tolerogenic phenotype,
Figure 3 Human PBMCs exposed to 1,25(OH)2D3 have increased GATA-3 to TBX21 ratios, associated with increased STAT6/TBX21 but
not Notch1/TBX21 ratios. A) Human PBMCs cultured for 3 days with 10 ng/mL of anti-CD3 demonstrate an increase in the STAT6 to TBX21
ratios by qPCR. N = 4 subjects, mean ± SD. B) Mouse PBMCs from EAE animals demonstrate an increase in GATA-3/TBX21 and STAT6/TBX21
ratios but not Notch1/TBX21 ratios by qPCR. N = 4 animals, mean ± SD, repeated twice. *P < 0.05; **p < 0.01; ***p < 0.001 compared to
controls.
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M2 phenotype that produces anti-inflammatory cyto-
kines (unpublished observations), altering B cell function,
decreasing chemokine gradients and reducing tissue-spe-
cific homing [13-15,46]. A significant literature in
humans also indicates that vitamin D increases the activ-
ity of regulatory T cells to prevent the excessive activa-
tion of autoreactive T cells [47,48]. These broad
spectrum effects of vitamin D likely contribute to the
apparent benefits of vitamin D in MS.
We sought in this manuscript to evaluate the impact
of vitamin D on the polarization of CD4+ T helper
Figure 4 Suppression of EAE clinical signs by 1,25(OH)2D3
occurs in wildtype but not STAT6 null mice. A) Wildtype (WT)
EAE-induced mice were treated with DMSO vehicle as controls, or
with 1,25(OH)2D3 (denoted as Vit D). There was complete
suppression of clinical signs in the 1,25(OH)2D3 treated group. N =
5 mice per group, and the trend of results has been reproduced in
2 other experiments. B) EAE was not suppressed in STAT6 null
(knockout, KO) mice by treatment with 1,25(OH)2D3, using the
identical dose regimen as for wildtype mice in panel A (100ng ip,
beginning at MOG immunization, and administered every other
day). N = 5 mice per group, repeated twice with similar results.
Figure 5 The elevation of GATA-3/T-bet ratio in EAE-afflicted
wildtype mice by 1,25(OH)2D3 did not occur in STAT6 null
mice. A) At sacrifice of the mice in Figure 4, spleens were removed
for RNA whereby qPCR was performed. The GATA-3/T-bet ratios
were increased by 1,25(OH)2D3 (denoted as Vit D) in wildtype (WT)
mice but this elevation did not occur in STAT6 null (knockout, KO)
mice. N = 5 per group, mean ± SEM, repeated twice. For panels B
and C, spleen and lymph nodes from the animals sacrificed in
Figure 4 were processed by Ficoll gradient centrifugation for
lymphocytes and these were left untreated, or were treated ex vivo
for 3 days with MOG (peptide 35-55), 1,25(OH)2D3 (denoted as Vit
D), or MOG plus 1,25(OH)2D3. In wildtype mice (panel B) that were
treated in vivo with vehicle or 1,25(OH)2D3, the ex vivo exposure to
1,25(OH)2D3, or MOG plus 1,25(OH)2D3, increased the GATA-3/T-bet
ratio; importantly, this increase did not occur in STAT6 KO mice
(panel C) whether they were exposed in vivo to vehicle or 1,25(OH)
2D3. Bars are mean ± SEM, N = 5 per group, repeated twice.
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of 1,25(OH)2D3 on generating human Th1 and Th17
subsets, and a predominance in elevating Th2 cells,
resulting in the consistent outcome of increased Th2 to
Th1 or Th17 ratios. These results were found by mea-
surements of representative cytokines for each subset,
and of their transcription factors. Similar results were
found for mouse T cells in culture. Extending to studies
in vivo, we found that mice treated with 1,25(OH)2D3
had significant generation of Th2 cells in the spleen and
lymph nodes detected through GATA-3 upregulation,
further emphasizing the predominance of Th2 cells gen-
erated through 1,25(OH)2D3 treatment.
In addressing the mechanism by which Th2 cells were
generated, our results have highlighted the STAT6 tran-
scription factor upstream of GATA-3, given the corre-
spondence of elevation of STAT6 and GATA-3 in
wildtype EAE mice treated with 1,25(OH)2D3, and of
the significant loss of effect of 1,25(OH)2D3 in increas-
ing GATA-3 levels in STAT6 null mice. Significantly,
the deficiency of STAT6 by using null mice resulted in
the inability of 1,25(OH)2D3 to alleviate EAE, and this
is linked mechanistically to the failure in STAT6 null
mice to elevate GATA-3 levels. Thus, our results have
highlighted not only the predominance of generation of
Th2 cells by vitamin D, but they have also revealed the
intermediary role of 1,25(OH)2D3 in engaging STAT6
to produce Th2 polarization.
Vitamin D has also been reported to lose its efficacy
in EAE when mice are deficient in IL-4 (20), IL-10 [49],
Rag-1 [50], vitamin D receptor [51] and estrogen recep-
tor signaling [50]. These results are consistent with our
results of the lack of efficacy of 1,25(OH)2D3 in STAT6
null mice since IL-4 and IL-10 are cytokines produced
by Th2 cells that require STAT6 for genesis, and the
Rag-1 mutation leads to defect in the generation of T
cells. A link between estrogen and vitamin D is demon-
strated by the findings that estrogen regulates the level
of the vitamin D receptor [50].
There are limitations to our current study that should
be considered. The T cell population following 3 days of
anti-CD3/CD28 stimulation of human peripheral blood-
derived mononuclear cells constitutes approximately
90% purity, so it is possible that the effect of 1,25(OH)
2D3 in generating Th2 predominance is indirect
through cells that contaminate the T cell cultures.
Moreover, our experiments utilize the known biologi-
cally active form of vitamin D, 1,25(OH)2D3, rather
than the precursors vitamin D3 or 25-hydroxyvitamin
D3. The last is the commonly measured form in humans
due to its stability compared to 1,25(OH)2D3, so our
results could be tempered by the potential differential
rates in humans of converting 25-hydroxyvitamin D3 to
1,25(OH)2D3. As well, we did not determine whether
other vitamin D metabolites, such as 24,25(OH)2D3,
influence T cell function; different vitamin D metabo-
lites can be found in MS patients and have been nega-
tively correlated with outcomes of magnetic resonance
imaging [52].
Another consideration is that while the concentrations
of 1,25(OH)2D3 that we used in culture can be achieved
in humans that are properly supplemented with vitamin
D, it remains to be determined how much 1,25(OH)2D3
is found in mice injected in this study with intraperito-
neal 1,25(OH)2D3. Our injection protocol and dose,
however, reproduce those used by other groups
[18,19,26,32,33]. Finally, it is of interest to determine
whether 1,25(OH)2D3 would be equally efficacious in
mice induced for EAE by active immunization with
MOG, as in the current study, compared to mice eli-
cited for EAE through the passive transfer of T cells; in
these 2 context, different mechanisms are initially
engaged to produce an inflammatory insult to the CNS,
and their responses to vitamin D could help discern the
key mechanisms for vitamin D in ameliorating EAE.
Conclusions
The utility of vitamin D in multiple sclerosis is contributed
by the polarization of helper T cells towards those that are
of the regulatory, anti-inflammatory Th2 type, even when
Th1 and Th17 levels are inconsistently modulated. The effi-
cacy of 1,25(OH)2D3 in generating Th2 cells and in alle-
viating EAE requires the STAT6 transcription factor that
lies upstream of GATA-3, raising the possibility that other
approaches to stimulate STAT6 may increase the effective-
ness of vitamin D. Thus, our results of the mechanistic
understanding of vitamin D activity have relevance to the
improvement of therapeutics to ameliorate MS.
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